Travere Therapeutics, Inc.
As of Oct 22, 2026, Travere Therapeutics is in Stage 3, the topping phase, now in its first week (since Oct 19, 2026). It closed at $52.43, 22.3% below its 52-week high and above its 200-day average, which is rising.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is TVTX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
TVTX among Biotechnology57th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …57 | TVTX | Stage 3 · wk 1 | 93 | −12.4% |
Travere Therapeutics: quick answers
What stage is Travere Therapeutics in?
As of Oct 22, 2026, Travere Therapeutics (TVTX) is in Stage 3, the topping phase. It entered Stage 3 on Oct 19, 2026 and is in its first week there. What the four stages mean
Is Travere Therapeutics in an uptrend?
Its uptrend has stalled. Travere Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 13.7% above its 200-day average, which is rising.
How far is Travere Therapeutics from its 52-week high?
Travere Therapeutics closed at $52.43 on Oct 22, 2026, 22.3% below its 52-week high of $67.52. Its 52-week low is $26.79.
How has Travere Therapeutics performed over the past year?
As of Oct 22, 2026, Travere Therapeutics is up 88.6% over the past year and up 32.7% so far in 2026.
Which sector and industry is Travere Therapeutics in?
Travere Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.